Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 163,562 | 120,282 | 251,453 | 141,102 | 108,973 |
| Cost of Goods | 30,419 | 11,347 | 6,337 | 5,366 | 5,571 |
| Gross Profit | 133,143 | 108,935 | 245,116 | 135,736 | 103,402 |
| Operating Expenses | 96,062 | -697,794 | 81,726 | 68,026 | 60,088 |
| Operating Income | 37,500 | 807,076 | 163,727 | 68,076 | 43,885 |
| Interest Expense | 27,415 | 35,745 | 48,276 | 13,460 | 12,842 |
| Other Income | -8,793 | 25,308 | 57,879 | 2,615 | -23,083 |
| Pre-tax Income | 1,292 | 796,639 | 173,330 | 57,231 | 7,960 |
| Income Tax | -5,306 | 167,337 | 30,009 | 44,675 | 10,327 |
| Net Income Continuous | 6,598 | 629,302 | 143,321 | 12,556 | -2,367 |
| Net Income Discontinuous | -9,583 | N/A | N/A | N/A | 731 |
| Net Income | $-2,985 | $629,302 | $143,321 | $12,556 | $-1,636 |
| EPS Basic Total Ops | -0.18 | 33.13 | 6.77 | 0.60 | -0.08 |
| EPS Basic Continuous Ops | 0.41 | 33.13 | 6.77 | 0.60 | -0.11 |
| EPS Basic Discontinuous Ops | -0.59 | N/A | N/A | N/A | 0.04 |
| EPS Diluted Total Ops | -0.18 | 31.85 | 5.96 | 0.53 | -0.08 |
| EPS Diluted Continuous Ops | 0.39 | 31.85 | 5.96 | 0.53 | -0.11 |
| EPS Diluted Discontinuous Ops | -0.57 | N/A | N/A | N/A | 0.04 |
| EPS Diluted Before Non-Recurring Items | 3.13 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $90,022 | $870,521 | $216,947 | $91,328 | $66,448 |